Sjoerd Rodenhuis

The Netherlands Cancer Institute — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

70h-index23.4kcitations343works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(88), Cancer Treatment and Pharmacology(68), Chemotherapy-induced organ toxicity mitigation(49), Lung Cancer Treatments and Mutations(35), HER2/EGFR in Cancer Research(35)

Publications342 total

Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
British Journal of Cancer·2023Open Access
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site
British Journal of Cancer·2020· 83 citedOpen Access
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer
UNC Libraries·2020Open Access
Abstract 1751: Systematic bias in genomic breast cancer classification due to selecting cases with high tumor percentage and good RNA quality
Cancer Research·2017
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer
Cancer Imaging·2017· 13 citedOpen Access
Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes
PLoS ONE·2017· 27 citedOpen Access
Abstract PD1-07: Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer
Cancer Research·2017
Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)
Cancer Research·2017
Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle
Cancer Research·2017· 1 cited
Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study
European Journal of Cancer·2017· 23 cited
PET/CT with 18 F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease
European Journal of Surgical Oncology·2016· 5 cited
Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
Breast Cancer Research·2016· 24 citedOpen Access
Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer
European Journal of Cancer·2016· 1 cited
Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study
Cancer Research·2016
Joint Accreditation Committee of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation accreditation for autologous hematopoietic stem cell transplantation in non-leukemic malignancies: burden or benefit?
Integrative Molecular Medicine·2016
Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?
Cureus·2015· 4 citedOpen Access
Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
Breast Cancer Research·2015· 76 citedOpen Access
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure
Breast Cancer Research and Treatment·2015· 6 cited
EZH2 is overexpressed in breast tumors with a BRCA1-like DNA copy number profile
Senologie - Zeitschrift für Mammadiagnostik und -therapie·2015
Abstract P3-06-21: Next generation sequencing to find predictors for chemotherapy response in triple negative breast cancer
Cancer Research·2015
page 1 of 18Next →

Frequent Co-authors

Jelle Wesseling(11), Marc J. van de Vijver(9), Emiel J. Rutgers(8), Robert J.C. Slebos(6), Harm van Tinteren(6), Esther H. Lips(6), Elsken van der Wall(5), Jos H. Beijnen(5), Jean‐Yves Blay(5), Jaap Verweij(5), Claudette E. Loo(5), Marie-Jeanne T. F. D. Vrancken Peeters(5), Elisabeth G.E. de Vries(5), Alwin D. R. Huitema(4), Marieke E. Straver(4), Sabine C. Linn(4), Juliane Hannemann(4), Lodewyk F.A. Wessels(4), Laura van ‘t Veer(3), Johannes L. Peterse(3)